Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Has Average Target Price of $8.60

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.60.

Several research firms have weighed in on AQST. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Thursday, October 15th. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th.

Aquestive Therapeutics Trading Down 4.5%

NASDAQ AQST opened at $4.04 on Tuesday. Aquestive Therapeutics has a 12-month low of $2.93 and a 12-month high of $6.93. The firm’s 50 day moving average is $4.67 and its 200-day moving average is $4.20.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. As a group, research analysts predict that Aquestive Therapeutics will post -0.50 EPS for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In related news, CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $4.22, for a total value of $105,500.00. Following the completion of the transaction, the chief executive officer directly owned 627,317 shares in the company, valued at approximately $2,647,277.74. The trade was a 3.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the transaction, the insider directly owned 235,689 shares of the company’s stock, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 58,750 shares of company stock worth $271,675 over the last three months. 6.81% of the stock is owned by insiders.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in Aquestive Therapeutics in the 3rd quarter worth $30,000. Elevation Point Wealth Partners LLC bought a new position in shares of Aquestive Therapeutics during the first quarter valued at about $42,000. ADAR1 Capital Management LLC boosted its holdings in shares of Aquestive Therapeutics by 103.9% during the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after purchasing an additional 264,000 shares during the period. Wealthfront Advisers LLC purchased a new stake in shares of Aquestive Therapeutics during the second quarter worth about $44,000. Finally, Legal & General Group Plc purchased a new stake in shares of Aquestive Therapeutics during the second quarter worth about $44,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.